Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota-University of Alberta-obesity-metabolic syndrome
- Development stage
- Unknown
- Lead developer
- University of Alberta
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is an investigational, donor-derived oral fecal microbiota transplantation intervention developed at the University of Alberta for severe obesity and metabolic syndrome. It was administered as a single oral dose of approximately 20 capsules containing screened fecal microbiota from lean healthy donors, with participants subsequently assigned to fiber supplementation regimens. The intended mechanism is engraftment or modulation of recipient gut microbial communities to improve microbial ecology and insulin sensitivity. In the Phase 2 randomized, double-blind trial NCT03477916, fecal microbial transplantation with low-fermentable fiber was associated with improved insulin sensitivity at 6 weeks in participants with severe obesity and metabolic syndrome. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03477916))
- Other names
- fecal microbiota transplantfecal microbial transplantationFMT
Beyond the preview
Go deeper on fecal microbiota-University of Alberta-obesity-metabolic syndrome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota-University of Alberta-obesity-metabolic syndrome.